117 related articles for article (PubMed ID: 9722129)
1. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
[TBL] [Abstract][Full Text] [Related]
2. Differential time-related effects of conjugated equine estrogen on bone metabolism in oophorectomized women.
Nozaki M; Inoue Y; Hashimoto K; Ogata R; Nakano H
Int J Gynaecol Obstet; 1998 Jan; 60(1):41-6. PubMed ID: 9506413
[TBL] [Abstract][Full Text] [Related]
3. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
5. Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
Katase K; Kato T; Hirai Y; Hasumi K; Chen JT
Calcif Tissue Int; 2001 Aug; 69(2):73-7. PubMed ID: 11683426
[TBL] [Abstract][Full Text] [Related]
6. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A
J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882
[TBL] [Abstract][Full Text] [Related]
7. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
Agnusdei D; Gennari C; Bufalino L
Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
[TBL] [Abstract][Full Text] [Related]
8. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
Jayo MJ; Register TC; Carlson CS
Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG
J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452
[TBL] [Abstract][Full Text] [Related]
10. The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism.
Hashimoto K; Nozaki M; Inoue Y; Sano M; Nakano H
Maturitas; 1995 Nov; 22(3):185-91. PubMed ID: 8746875
[TBL] [Abstract][Full Text] [Related]
11. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate.
Prior JC; Vigna YM; Wark JD; Eyre DR; Lentle BC; Li DK; Ebeling PR; Atley L
J Bone Miner Res; 1997 Nov; 12(11):1851-63. PubMed ID: 9383690
[TBL] [Abstract][Full Text] [Related]
12. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
[TBL] [Abstract][Full Text] [Related]
13. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.
Fujita T; Fujii Y; Miyauchi A; Takagi Y
J Bone Miner Metab; 1999; 17(4):289-95. PubMed ID: 10575594
[TBL] [Abstract][Full Text] [Related]
15. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
16. [Ipriflavone].
Kitatani K; Morii H
Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ipriflavone in established osteoporosis and long-term safety.
Agnusdei D; Bufalino L
Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
[TBL] [Abstract][Full Text] [Related]
20. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
